{"DataElement":{"publicId":"2932333","version":"1","preferredName":"Oncogene K-Ras Assessment Ind-2","preferredDefinition":"the yes/no indicator related to status determination of human Oncogene K-Ras which is a mutated variant of KRAS2 Gene that encodes two alternative isoforms of monomeric p21 K-RAS protein, a monomeric GTPase involved in transmembrane signal transduction that alternates between inactive GDP-bound and active GTP-bound forms.","longName":"ONCKRAS_ASS_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2932331","version":"1","preferredName":"Oncogene K-Ras Assessment","preferredDefinition":"information related to status determination of human Oncogene K-Ras which is a mutated variant of KRAS2 Gene that encodes two alternative isoforms of monomeric p21 K-RAS protein, a monomeric GTPase involved in transmembrane signal transduction that alternates between inactive GDP-bound and active GTP-bound forms.","longName":"KRAS_ASSESS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2932329","version":"1","preferredName":"Oncogene K-Ras","preferredDefinition":"Human Oncogene K-Ras is a mutated variant of KRAS2 Gene, which encodes two alternative isoforms of monomeric p21 K-RAS protein, a monomeric GTPase involved in transmembrane signal transduction that alternates between inactive GDP-bound and active GTP-bound forms. K-Ras is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase-activating protein. Mitogen-stimulated RAS stabilizes MYC protein and enhances MYC accumulation by the RAS/RAF/MAPK pathway, which appears to inhibit the proteasome-dependent degradation of MYC. Implicated in a variety of human tumors, mutations of specific amino acids activate RAS to transform cells. KRAS is involved in malignancy much more often than is HRAS. Oncogene K-Ras disrupts normal cell function.","longName":"C16766","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncogene K-Ras","conceptCode":"C16766","definition":"Human Oncogene K-Ras is a mutated variant of KRAS2 Gene, which encodes two alternative isoforms of monomeric p21 K-RAS protein, a monomeric GTPase involved in transmembrane signal transduction that alternates between inactive GDP-bound and active GTP-bound forms. K-Ras is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase-activating protein. Mitogen-stimulated RAS stabilizes MYC protein and enhances MYC accumulation by the RAS/RAF/MAPK pathway, which appears to inhibit the proteasome-dependent degradation of MYC. Implicated in a variety of human tumors, mutations of specific amino acids activate RAS to transform cells. KRAS is involved in malignancy much more often than is HRAS. Oncogene K-Ras disrupts normal cell function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70F4BA3C-486C-66D6-E040-BB89AD4323AD","latestVersionIndicator":"Yes","beginDate":"2009-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-12","modifiedBy":"ONEDATA","dateModified":"2009-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233077","version":"1","preferredName":"Assessment","preferredDefinition":"The final result of a determination of the value, significance, or extent of.","longName":"C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F90B5E56-BAFE-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-08","modifiedBy":"ONEDATA","dateModified":"2005-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70F4BA3C-487A-66D6-E040-BB89AD4323AD","latestVersionIndicator":"Yes","beginDate":"2009-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"5777527","version":"1","longName":"Pancreatic","context":"OCG"}]}],"AlternateNames":[{"name":"OCG","type":"USED_BY","context":"OCG"},{"name":"Oncogene_K-ras_assessment","type":"HCMI Name","context":"OCG"}],"ReferenceDocuments":[{"name":"KRAS mutant status determined","type":"Preferred Question Text","description":"KRAS mutant status determined by central testing, or KRAS status not evaluable","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"KRAS status known","url":null,"context":"CTEP"},{"name":"HCMI Question Text","type":"Alternate Question Text","description":"KRAS mutation found?","url":null,"context":"OCG"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"70F4BA3C-488C-66D6-E040-BB89AD4323AD","latestVersionIndicator":"Yes","beginDate":"2009-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-12","modifiedBy":"COOPERM","dateModified":"2017-08-31","changeDescription":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}